Stemline Therapeutics Banner Image

Stemline Therapeutics

  • Ticker STML
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Stemline Therapeutics Logo Image
  • 11-50 Employees
  • Based in New York City, New York
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-701, and SL-801. A potentially pivotal Phase 2 trial with SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R; CD123) present on a wide range of hematologic cancers, is currentlyMore enrolling patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Stemline Therapeutics

Most Recent Annual Report

Stemline Therapeutics
MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Stemline Therapeutics has reached its limit for free report views.

Stemline Therapeutics does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports